Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Board declares interim dividend of Rs 2 per equity share
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Board approves fundraise of Rs 1500 crore
The company expects revenue growth of 10-15 per cent in the US
PAT rises to Rs 195.76 crore
Subscribe To Our Newsletter & Stay Updated
